Researchers at The Pirbright Institute have secured almost $1.5 million from the Bill and Melinda Gates Foundation to fund the development of improved foot-and-mouth disease (FMD) vaccines for East Africa.
Studies assessing the effectiveness of anti-viral treatments for swine flu and those seeking to understand the behaviour of the virus, must factor in the route of infection during experiments, as this has a greater impact on results than previously thought, a new study from The Pirbright Institute has found.
Influenza A virus (IAV) is a global health threat. The infection in pigs causes severe disease when combined with other respiratory pathogens, and can result in considerable economic losses to farmers, and poses a significant risk to humans too.
Scientists at The Pirbright Institute have been encouraged by the results from a potential new vaccine candidate against Marek’s disease (MD). Using a recombinant (new combinations of genetic material) adenovirus which carries a single gene from a virulent strain of Marek’s disease virus, they are hopeful that further research and trials could lead to the production of an effective MD vaccine that is cheaper and easier to produce - and crucially has no possibility of reverting to a virulent strain.